Silas Inman, Senior Vice President, Content, joined MJH Life Sciences™ in early 2011 as one of the company's first web editors. In this position, he built OncLive.com from a fledgling web platform to a leading source of oncology news for community oncologists via in-depth reporting of breaking news from major medical conferences and the launch of OncLive® TV.
Throughout his tenure at MJH, Silas has been accountable for several organic launches of highly successful brands, including Targeted Oncology™ and NeurologyLive®, and for quickly transforming acquisitions into high-functioning business units. Prior to joining MJH, Silas, who attended Eastern Michigan University, was an EMT, frontend web developer, and social media/SEO expert. Follow him on Twitter @SilasInman or email him at sinman@mjhlifesciences.com
FDA Grants Priority Review to Daratumumab Triplets for Relapsed Myeloma
October 8th 2016The FDA has granted a priority review designation to daratumumab (Darzalex) in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone for patients with relapsed multiple myeloma following at least 1 prior therapy.
Read More
Frontline Carfilzomib Not Superior to Bortezomib in Phase III Myeloma Study
September 27th 2016Carfilzomib did not improve progression-free survival compared with bortezomib when used in combination with melphalan and prednisone as a treatment for transplant ineligible patients with newly diagnosed multiple myeloma.
Read More
Encorafenib/Binimetinib Combo Improves PFS Versus Vemurafenib in Phase III Melanoma Study
September 26th 2016The combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib improved progression-free survival compared with single-agent vemurafenib for patients with BRAF-mutant melanoma.
Read More
CHMP Issues Positive Opinion for Ixazomib Conditional Approval in Myeloma
September 17th 2016The CHMP has recommended a conditional approval for ixazomib in combination with lenalidomide and dexamethasone as a treatment for patients with multiple myeloma who have received at least 1 prior therapy.
Read More
Tesaro Initiates Rolling Submission for Niraparib in Ovarian Cancer
September 12th 2016The FDA has granted a fast track designation to niraparib, allowing the initiation of a rolling submission of data for potential approval for the PARP inhibitor as a treatment for women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.
Read More
FDA Submission Completed for Brigatinib in ALK-Positive NSCLC
August 30th 2016A new drug application has been submitted for brigatinib (AP26113) as a potential treatment for patients with advanced ALK-positive non–small cell lung cancer following resistance or intolerance to crizotinib (Xalkori).
Read More
Venetoclax Shows Single-Agent Activity in AML
August 16th 2016Treatment with single-agent BCL-2 inhibitor venetoclax demonstrated an overall response rate of 19% with a tolerable safety profile in patients who were unfit for intensive chemotherapy for those with relapsed/refractory acute myeloid leukemia.
Read More
Selumetinib Fails to Improve PFS in Phase III Lung Cancer Study
August 9th 2016The combination of selumetinib and docetaxel failed to improve survival compared with docetaxel alone as a second-line treatment for patients with KRAS-mutant locally advanced or metastatic non–small cell lung cancer.
Read More
FDA Grants Ribociclib Breakthrough Designation for Breast Cancer
August 3rd 2016The FDA has granted a breakthrough therapy designation to the CDK4/6 inhibitor ribociclib in combination with letrozole for its potential as a frontline therapy for patients with HR-positive, HER2-negative advanced breast cancer.
Read More
Novel Treatment Strategies Emerging for CLL
July 27th 2016Ibrutinib (Imbruvica) and idelalisib (Zydelig) have become standard of care treatments for patients with relapsed or high-risk chronic lymphocytic leukemia, with ongoing studies in progress to move ibrutinib into the frontline setting.
Read More
Novel Combination Study Planned for SCLC
July 25th 2016A phase I/II study will explore the delta-like protein 3-targeted antibody-drug conjugate rovalpituzumab tesirine (Rova-T) with the PD-1 inhibitor nivolumab (Opdivo) alone or in combination with the CTLA-4 inhibitor ipilimumab (Yervoy) for patients with relapsed extensive-stage small cell lung cancer.
Read More
CHMP Adopts Positive Opinion for Liposomal Irinotecan in Pancreatic Cancer
July 25th 2016The Committee for Medicinal Products for Human Use has recommended the approval of pegylated liposomal irinotecan (Onivyde) in combination with fluorouracil and leucovorin for patients with metastatic pancreatic adenocarcinoma following progression on a gemcitabine-based therapy.
Read More
Crizotinib Receives Positive CHMP Opinion for ROS1-Positive NSCLC
July 25th 2016The Committee for Medicinal Products for Human Use has adopted a positive option for crizotinib (Xalkori) as a treatment for adults with ROS1-positive advanced non–small cell lung cancer, suggesting an approval may be imminent.
Read More
Neratinib Benefit in Breast Cancer Sustained in 5-Year ExteNET Analysis
July 22nd 2016A 5-year assessment showed that neratinib reduced the risk of invasive disease recurrence or death by 26% compared with placebo as extended adjuvant therapy for patients with HER2-positive early stage breast cancer following 12 months of trastuzumab.
Read More
Role of Targeted Therapies Evolving in CLL
July 20th 2016The treatment landscape for patients with chronic lymphocytic leukemia continues to evolve, as long-term data become available from pivotal studies that led to the FDA approvals for the BTK inhibitor ibrutinib (Imbruvica) and the PI3K inhibitor idelalisib (Zydelig).
Read More